STAT3 and ovarian cancer: We demonstrate, for the first time, that inhibition of EGFR significantly increased phosphorylation of STAT3 in ovarian cancer cells and blocking STAT3 activation led to enhanced anti-tumor activity of gefitinib both in vitro and in vivo.